Background: The aim of the present work was to determine the health-related quality of life (HRQOL) of our patients on hemodialysis using the COOP/WONCA charts. A further aim was to explore its psychometric characteristics. Methods: The present study included all patients attending the hemodialysis unit of our hospital. The comparative study of the results was conducted with other population groups in which this questionnaire has been applied previously (primary-care patients, their accompanying persons, pregnant women, Alzheimer patient carers and drug addicts). The dimensional structure of the questionnaire was explored by factorial analysis of principal components, and internal consistency was evaluated with the Cronbach α factor. Concurrent validity was determined by comparative analysis of the results of the COOP/WONCA charts with those of another questionnaire, the 36-item short form of the Quality of Life Score (SF-36). To do so, 60 randomly chosen patients completed both questionnaires. Results: 98.9% of patients completed the COOP/WONCA charts in their entirety. The mean scores of all the charts, with the exception of overall health, are in the range of what could be called ‘favorable area of quality of life’ (below 3). With respect to the rest of the groups, the dialysis patients had the best scores on the ‘feelings’ and ‘social activities’ charts and none of the worst ones. The joint factorial analysis revealed that the questionnaire has a 3-factor structure: factor 1 or daily functioning, factor 2 or quality of life and health, factor 3 or the psychosocial factor. The Cronbach α value for the 9 charts was 0.766. All the correlations between equivalent dimensions of questionnaires COOP/WONCA and SF-36 were statistically significant (p < 0.01). The convergent validity mean was 0.57 and the discriminant validity mean was 0.22, appreciably lower than convergent validity. Conclusions: This study shows that the process of psychological adaptation to problems deriving from dialysis is satisfactory. Moreover, the COOP/WONCA charts are a useful instrument for the determination of the HRQOL in hemodialysis patients without losing psychometric quality.

1.
Jofre R, López-Gómez JM, Valderrábano F: Quality of life for patient groups. Kidney Int 2000;57(suppl 74):121–130.
2.
Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the Kidney Disease Quality of Life (KDQOLTM) instrument. Qual Life Res 1994;3:329–338.
3.
Meyer KB, Espindle DM, DeGiacomo JM, Jenuleson CS, Kurtin PS, Davies AR: Monitoring dialysis patients’ health status. Am J Kidney Dis 1994;24:267–279.
4.
Kanh IH, Garratt AM, Kumar A, Cody DJ, Catto GR, Edward N, MacLeod AM: Patient perception on renal replacement therapy: evaluation using a new instrument. Nephrol Dial Transplant 1995;10:684–689.
5.
Carmichael P, Popoola J, John I, Stevens PE, Carmichael AR: Assessment of quality of life in a single centre dialysis population using the KDQOL-SFTM questionnaire. Qual Life Res 2000;9:195–205.
6.
Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT: Quality of life over time in dialysis: The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int 1999;56:720–728.
7.
Bremer BA, McCauley CR, Wrona RM, Johnson JP: The quality of life in end-stage renal disease: a reexamination. Am J Kidney Dis 1989;13:200–209.
8.
Evans RW, Manninen DL, Garrison LP, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553–559.
9.
Johnson JP, McCauley CR, Copley JB: The quality of life of hemodialysis and transplant patients. Kidney Int 1982;22:286–291.
10.
Auer J, Gokal R, Stout JP, Hillier VF, Kincey J, Simon LG, Oliver DO: The Oxford-Manchester study of dialysis patients: age, risk factors and treatment method in relation to quality of life. Scand J Urol Nephrol 1990;131(suppl):31–37.
11.
De-Nour AK, Shanan J: Quality of life of dialysis and transplanted patients. Nephron 1980;25:117–120.
12.
Gutmann RD: Renal transplantation. N Engl J Med 1979;301:975–982.
13.
Deniston OL, Carpentier-Alting P, Kneisley J, Hawthorne VM, Port FK: Assessment of quality of life in end-stage renal disease. Health Serv Res 1989;24:555–578.
14.
Kimmel PL: Just whose quality of life is it anyway? Controversies and consistencies in measurements of quality of life. Kidney Int 2000;57(suppl 74):113–120.
15.
Hays RD, Kallich JD, Mapes DL, Coons SJ, Amin N, Carter WB: Kidney Disease Quality of Life Short Form (KDQOL-SF), Version 1.2 – A Manual for Use and Scoring. Santa Monica, RAND (P-7298), 1995.
16.
Brazier JE, Walters SJ, Nicholl JP, Kohler B: Using the SF-36 and Euroqol on an elderly population. Qual Life Res 1996;5:195–204.
17.
Martín-Díaz F, Reig-Ferrer A, Sarró F, Ferrer-Cascales R, Arenas D, González F, Gil T: Evaluación de la calidad de vida en pacientes de una Unidad de Hemodiálisis con el cuestionario Kidney Disease Quality of Life–Short Form (KDQOL-SF). Rev Esp Diál Trasplant 2004;25:79–92.
18.
Lizán-Tudela L, Reig-Ferrer A: Adaptación transcultural de una medida de la calidad de vida relacionada con la salud: la versión española de las viñetas COOP/WONCA. Aten Primaria 1999;24:75–82.
19.
Sadler JH, Blagg CR, Wasson JH: New dialysis-specific COOP charts may improve ESRD patient assessment. Nephrol News Issues 1998;12:41–42.
20.
Khan IH: Comorbidity: the major challenge for survival and quality of life in end stage renal disease. Nephrol Dial Transplant 1998;13(suppl 1):76–79.
21.
Nelson EC, Wasson J, Kirk J, Keller A, Clark D, Dietrich A, Stewart A, Zubkoff M: Assessment of function in routine clinical practice: description of the COOP chart method and preliminary findings. J Chron Dis 1987;40(suppl):S55–S63.
22.
Van Weel C, König-Zahn C, Touw-Otten FWMM, et al: COOP/WONCA Charts – A Manual. Groningen, World Organization of Family Doctors, European Research Group on Health Outcomes, Northern Centre for Health Care Research, University of Groningen, 1995.
23.
Lizán-Tudela L, Reig-Ferrer A, Richart-Martinez M, Gabrero-Garcia J: Evaluación de la calidad de vida relacionada con la salud mediante las láminas COOP/WONCA. Med Clin (Barc) 2000;114(suppl 3):76–80.
24.
Alonso J, Prieto L, Antó JM: La versión española del SF-36 Health Survey (Cuestionario de salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 1995;104:771–776.
25.
Lizán-Tudela: Adaptación de una medida de la calidad de vida relacionada con la salud en atención primaria: la versión española de las viñetas COOP/WONCA; tesis doctoral, Universidad Miguel Hernández, 1997.
26.
Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S: Self-assessed physical and mental function of haemodialysis patients. Nephrol Dial Transplant 2001;16:1387–1394.
27.
Landgraf JM, Nelson EC and the Darmouth COOP Primary Care Network: Summary of the WONCA/COOP International Health Assessment Field Trial. Aust Fam Physician 1992;21:255–269.
28.
McHorney CA, Tarlov AR: Individual patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995;4:293–307.
29.
Van Weel C: Functional status in primary care: COOP/WONCA charts. Disab Rehab 1993;15:96–101.
30.
Hays RD, Anderson R, Revicki D: Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993;2:441–449.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.